Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system
- PMID: 33678452
- DOI: 10.1016/j.vaccine.2021.02.052
Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system
Abstract
On October 7, 2016, the Food and Drug Administration approved recombinant hemagglutinin quadrivalent influenza vaccine (RIV4) (Spodoptera frugiperda cell line; Flublok Quadrivalent) for active immunization for the prevention of influenza disease in individuals 18 years of age and older. Clinical trials did not reveal any major differences in adverse events or serious adverse events following Flublok Quadrivalent versus standard-dose quadrivalent inactivated influenza vaccine. To improve our understanding of the safety profile of this vaccine, we reviewed and summarized adverse event reports after Flublok Quadrivalent administration to the Vaccine Adverse Event Reporting System (VAERS). Through June 30, 2020, VAERS received 849 reports after RIV4 vaccination. The vast majority (810; 95%) were non-serious. Among serious events, there were 10 cases of Guillain-Barré syndrome, including 5 people who required mechanical ventilation and 2 people who died. Many allergic reactions were reported as non-serious, but required interventions to treat a life-threatening event, e.g., epinephrine, nebulizers, albuterol, glucocorticoids, and supplemental oxygen. Two people experienced a positive rechallenge (i.e., allergic reactions after repeated vaccination with RIV4), including a person who-despite premedication with antihistamines-developed respiratory difficulties, required epinephrine, and was transported to the emergency department. The occurrence of anaphylaxis and other allergic reactions in some individuals may reflect an underlying predisposition to atopy that may manifest itself after an exposure to any drug or vaccine, and does not necessarily suggest that Flublok Quadrivalent is particularly allergenic. Postmarketing safety surveillance will continue to be vital for understanding the benefits and risks of quadrivalent recombinant influenza vaccine.
Keywords: Adverse event; Influenza; Postmarketing safety; Vaccine.
Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.Vaccine. 2022 Feb 11;40(7):1026-1030. doi: 10.1016/j.vaccine.2021.12.070. Epub 2022 Jan 12. Vaccine. 2022. PMID: 35031148 Clinical Trial.
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
-
Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.Vaccine. 2019 Mar 7;37(11):1516-1520. doi: 10.1016/j.vaccine.2019.01.052. Epub 2019 Feb 7. Vaccine. 2019. PMID: 30739795
-
Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.Vaccine. 2017 Oct 9;35(42):5618-5621. doi: 10.1016/j.vaccine.2017.08.047. Epub 2017 Sep 5. Vaccine. 2017. PMID: 28886946
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
Cited by
-
Summary of the National Advisory Committee on Immunization (NACI) Supplemental Statement on Recombinant Influenza Vaccines.Can Commun Dis Rep. 2022 Sep 1;48(9):383-391. eCollection 2022 Sep 1. Can Commun Dis Rep. 2022. PMID: 38116047 Free PMC article.
-
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2022-2023.Can Commun Dis Rep. 2022 Sep 1;48(9):373-382. eCollection 2022 Sep 1. Can Commun Dis Rep. 2022. PMID: 38116046 Free PMC article.
-
Examining the Negative Sentiments Related to Influenza Vaccination from 2017 to 2022: An Unsupervised Deep Learning Analysis of 261,613 Twitter Posts.Vaccines (Basel). 2023 May 23;11(6):1018. doi: 10.3390/vaccines11061018. Vaccines (Basel). 2023. PMID: 37376407 Free PMC article.
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1. MMWR Recomm Rep. 2022. PMID: 36006864 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical